The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy

Cancer Cell

Fecha de publicación: 8 July 2019

DOI: https://doi.org/10.1016/j.ccell.2019.06.001

Autores: Irene Catalano, Livio Trusolino

Background: In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.